Conference Notes
Semi permanent Make-up removal with Lasers
Friday, December 12th, 2014Semi permanent tattoos are often used to alleviate tedious daily make-up but they also, like other tattoos can become cosmetically unacceptable. Treatment: Available classical treatments include, surgery, dermabrasion but both induce scarring which is not acceptable for patients who are looking for a cosmetic procedure to correct another one. Q-Switched lasers have been tried and […]
Tuberous Sclerosis Treatment with topical Rapamycin: Beyond treating Facial Angiofibromas
Friday, December 12th, 2014Tuberous Sclerosis (TSC) is a multisytemic condition characterized by numerous skin signs (shagreen patch, ash leaf macules…). Of these, hypomelanotic macules are the most frequent sign and are present in 90% of patients with TSC. (Macules have to be 3 or more in number to fit in the diagnosis of TSC). The cause of TSC […]
Hidradenitis Suppurativa (Acne Inversa): More evidence on how to treat it
Saturday, October 11th, 2014Epidemiology of Hidradenitis suppurativa (HS) also called Acne Inversa (Jemec) -Prevalence is anywhere between 0.0033% (genetic hypothesis) to 4% (self reporting in nurses) -In a big study in immigrants comparing with Spanish citizens, prevalence of HS was found to reach 0.2% up to 0.9% in Spanish citizens. prevalence is anywhere between 0.0033% (genetic hypothesis) to […]
Erythrodermic Psoriasis Treatment with Ustekinumab
Saturday, October 11th, 2014Erythrodermic psoriasis (EP) is a generalized, inflammatory erythematous dermatosis, with or without exfoliation lasting for at least 3 months involving 75% or more of the body surface Methods: In this retrospective study PASI evaluation was done at 4, 16 and 28 weeks of treatment 22 patients dosage of 45mg in 16 patients dosage of 90mg […]
Brodalumub: also effective against Nail and Scalp Psoriasis
Saturday, October 11th, 2014Brodalumab (KHK4827, also known as AMG827) is a monoclonal antibody that binds to human IL-17RA and blocks the biological activities of IL-17A, 17F, 17A/F and IL-17E It has been shown to improve plaque psoriasis and psoriatic arthritis in 12 weeks. Goal: efficacy of KHK4827 for nail nail and scalp psoriasis in Japanese patients with moderate […]
The Benefits of Sunscreens: Protective Cellular Effects from Ultraviolet A Rays
Saturday, October 11th, 2014Lipofucsin is the intracellular aggregate of oxidized proteins and lipids. It is a marker of autophagy and is stainable on immunochemistry with Sudan Black B (SBB) Ultraviolet A (UVA) damage induces DNA damage, oxidation of proteins and lipids, autophagy and subsequently apoptosis (provided exposure is long enough) In this study human cultures of fibroblasts were […]
Palmoplantar Psoriasis Treatment with Ustekinumab
Saturday, October 11th, 2014Introduction: Palmoplantar psoriasis presents as sterile pustules with hyperkeratosis, erythema, scaling and fissuring on the palms and soles Treatment is challenging. topicals don’t really work and acitretin is not always effective. Methodology: prospective study 9 patients, mean age 48 years old ustekinumab administered subcutaneously at weeks 0,4 and then every 12 weeks evaluation with PPPASI […]
PRP to treat Vitiligo ?
Saturday, October 11th, 2014PRP is an autologous platelet concentrate in a small volume of plasma obtained from high speed centrifugation of the patient blood sample Methods 26 patients with vitiligo (type and location not specified) Intradermal intralesional PRP injection was done every 2 weeks until a response was observed or improvement was seenscoring with the Vitiligo European task […]
Adalimumab vs Etanercept in Quality of Life Improvement
Saturday, October 11th, 2014Adalimumab showed a slightly higher reduction in PASI after 1 year, however it proved an equivalent efficacy to Etanercept after an extensive follow-up (up to 5 years) Contrarily to etanercept, adalimumab patients showed a progressive improvement with DLQI (84 to 77) For both groups, sustained response (PASI75 maintenance of results 60 months after initiation of […]
Biologic Therapy for Psoriasis: Paradoxical Reactivation of Psoriasis on Infliximab
Saturday, October 11th, 2014Infliximab is an anti-TNF biologic It is used in the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease A case report from Spain: 32 year old female known for Crohn’s disease no response to mesalazine and systemic corticosteroids was subsequently put on infliximab at a dosage 5mg/kg for a duration of 10 years she […]
